nach oben

European Journal of Drug Metabolism and Pharmacokinetics

Erschienen in:

01.03.2011 | Original Paper

Effect of blood decrease on micafungin disposition in rats

verfasst von: Hiroki Konishi, Keizo Fukushima, Masatomo Sudo, Masaki Sumi, Tokuzo Minouchi, Ikumi Iga, Nobuhito Shibata, Akira Yamaji

Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Micafungin (MCFG) is a novel echinocandin-class antifungal agent that extensively undergoes metabolic removal in the liver. In the present study, the influence of decreased blood volume on pharmacokinetic disposition of MCFG was examined using a rat model prepared by phlebotomy. In phlebotomized rats, hematocrit level and plasma albumin concentration were decreased by 50 and 15%, respectively. Regarding the pharmacokinetic parameters of MCFG, there were no significant differences in the total body clearance (CL_tot) and elimination rate constant (k _e) between control and phlebotomized rat groups. A slight increase was observed in the apparent volume of distribution at steady-state (Vd_ss), but the degree of change was minimal. These findings demonstrate that the elimination capacity for MCFG is only slightly affected by severe anemia and moderate hypoalbuminemia, and provide experimental evidence for the preceding clinical studies suggesting that neither hematocrit level nor serum albumin concentration is a contributory factor for the metabolic clearance of MCFG.

Abe F, Ueyama J, Kawasumi N et al (2008) Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats. Antimicrob Agents Chemother 52:3454–3456PubMedCrossRef

Azuma J, Nakahara K, Kagayama A, Kajiho T, Kawamura A, Suematsu H, Mukai T (2002) Phase I study of micafungin. Jpn J Chemother 50:S104–S147

Chandrasekar PH, Sobel JD (2006) Micafungin: a new echinocandin. Clin Infect Dis 42:1171–1178PubMedCrossRef

Dager WE, Inciardi JF, Howe TL (1995) Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother 29:667–670PubMed

DiPiro JT, Hooker KD, Sherman JC, Gaines MG, Wynn JJ (1992) Effect of experimental hemorrhagic shock on hepatic drug elimination. Crit Care Med 20:810–815PubMedCrossRef

Dubniks M, Persson J, Grände PO (2007) Plasma volume expansion of 5% albumin, 4% gelatin, 6% HES 130/0.4, and normal saline under increased microvascular permeability in the rat. Intensive Care Med 33:293–299PubMedCrossRef

Fradette C, Du Souich P (2004) Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab 5:257–271PubMedCrossRef

Hatano K, Morishita Y, Nakai T, Ikeda F (2002) Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot 55:219–222PubMed

Hebert MF, Smith HE, Marbury TC et al (2005) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45:1145–1152PubMedCrossRef

Hiemenz J, Cagnoni P, Simpson D et al (2005) Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 49:1331–1336PubMedCrossRef

Johnson KB, Egan TD, Kern SE et al (2003) The influence of hemorrhagic shock on propofol: a pharmacokinetic and pharmacodynamic analysis. Anesthesiology 99:409–420PubMedCrossRef

Joseph JM, Jain R, Danziger LH (2007) Micafungin: a new echinocandin antifungal. Pharmacotherapy 27:53–67PubMedCrossRef

Kaneko H, Yamato Y, Teramura Y et al (2002) Metabolites of micafungin in rats and dogs. Jpn J Chemother 50:S88–S93

Konishi H, Sudo M, Sumi M, Morii H, Minouchi T, Aimoto T, Yamaji A (2005) Pharmacokinetic behavior of micafungin in rats with carbon tetrachloride-induced acute hepatic failure. Biol Pharm Bull 28:556–559PubMedCrossRef

Konishi H, Fukushima K, Sudo M et al (2010) Reduced elimination clearance of micafungin in rats with cholestatic hyperbilirubinemia. Fundam Clin Pharmacol 24:457–462PubMedCrossRef

McLean AJ, Morgan DJ (1991) Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 21:42–69PubMedCrossRef

Numeroso F, Barilli AL, Delsignore R (2008) Prevalence and significance of hypoalbuminemia in an internal medicine department. Eur J Intern Med 19:587–591PubMedCrossRef

Saavedra S, Jarque I, Sanz G et al (2002) Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institution. Clin Microbiol Infect 8:725–733PubMedCrossRef

Shibata N, Shimakawa H, Minouchi T, Yamaji A (1993) Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states. Biol Pharm Bull 16:1130–1135PubMed

Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, Hata T (1999) Moment analysis program available on Microsoft Excel^®. Xenobio Metabol Dispos 14:286–293

Tabata K, Katashima M, Kawamura A, Kaibara A, Tanigawara Y (2006) Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. Drug Metab Pharmacokinet 21:324–331PubMedCrossRef

Tomishima M, Ohki H, Yamada A, Takasugi H, Maki K, Tawara S, Tanaka H (1999) FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot 52:674–676PubMed

Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II, Kontoyiannis DP (2003) Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 98:86–93PubMedCrossRef

Yamato Y, Kaneko H, Hashimoto T et al (2002a) Pharmacokinetics of the antifungal drug micafungin in mice, rats and dogs, and its in vitro protein binding and distribution to blood cells. Jpn J Chemother 50:S74–S79

Yamato Y, Kaneko H, Yamasaki S et al (2002b) Distribution and excretion of intravenous dosing of [¹⁴C] micafungin to rats. Jpn J Chemother 50:S80–S87

Titel: Effect of blood decrease on micafungin disposition in rats
verfasst von: Hiroki Konishi
Keizo Fukushima
Masatomo Sudo
Masaki Sumi
Tokuzo Minouchi
Ikumi Iga
Nobuhito Shibata
Akira Yamaji
Publikationsdatum: 01.03.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics / Ausgabe 1/2011
Print ISSN: 0378-7966
Elektronische ISSN: 2107-0180
DOI: https://doi.org/10.1007/s13318-011-0023-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Effect of blood decrease on micafungin disposition in rats

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Assessment and modulation of phillyrin absorption by P-gp using Caco-2 cells and MDR1-MDCKII cells

Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients

Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers